Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo's €2.6bn Ablynx Bid Opens The Door For Better Offers

Executive Summary

Gilead, Amgen and AbbVie are names that could join the fray should a bidding war start for Nanobody drug developer Ablynx, which has rebuffed two takeover offers from Novo Nordisk.


Related Content

Ablynx, Bioverativ Buys Drive Sanofi's Hematology Reign
Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition
Which Biotechs Enjoyed A 'JPM Jump' - And Which Lost Out?
Evox To Raise Cash In 2018 For Novel Exosome Platform
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts